Recursion Pharmaceuticals in the spotlight

Assessing $RXRX financials and fundamentals

Boutique Biotech spoke to the CFO of Recursion Pharmaceuticals ($RXRX) last week to learn more about the company and its financials. Here’s what we learned:

$RXRX ended Q1 2021 with $219M in cash. Burned $30M that quarter. At current burn rate, they have approx. cash to last until end of 2022. However, company expects to launch three Phase 2 trials i…